Linked Life Data

2835476

Source:http://linkedlifedata.com/resource/pubmed/id/2835476

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2835476rdf:typepubmed:Citationlld:pubmed
pubmed-article:2835476lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C0040300lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C0540641lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C0332256lld:lifeskim
pubmed-article:2835476lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:2835476pubmed:issue2lld:pubmed
pubmed-article:2835476pubmed:dateCreated1988-6-16lld:pubmed
pubmed-article:2835476pubmed:abstractTextThe affinities of 34 adrenergic antagonists for alpha-2 adrenergic receptors were determined from homogenate radioligand binding studies using [3H]yohimbine and [3H]rauwolscine. It has been suggested that alpha-2 adrenergic receptors can be subdivided into alpha-2A and alpha-2B subtypes. Oxymetazoline is selective for alpha-2A receptors, whereas prazosin is alpha-2B selective. Five different tissues were used, each of which has only one of the two subtypes: human platelet (alpha-2A), HT29 cell line (alpha-2A), human cerebral cortex (alpha-2A), neonatal rat lung (alpha-2B), and NG108-15 cell line (alpha-2B). The drug affinities were highly correlated when alpha-2A tissues were compared with alpha-2A tissues (r = 0.97 to 0.98) or when the two alpha-2B tissues were compared (r = 0.99). By contrast, comparison of an alpha-2A tissue with an alpha-2B tissue resulted in poor correlations (r = 0.77 to -0.87). Three new subtype selective drugs were identified among these drugs on the basis of at least a 10-fold greater affinity for one subtype. All three were selective for the alpha-2B subtype: ARC-239 (100-fold selective), chlorpromazine (18-fold selective), and 7-hydroxychlorpromazine (17-fold selective). These studies, by demonstrating distinct pharmacological profiles for the two alpha-2 adrenergic receptor subtypes in several different tissues, further support the existence and definition of these subtypes. The identification of a cell line for each subtype should be useful in the further study of alpha-2 adrenergic receptor subtypes.lld:pubmed
pubmed-article:2835476pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:languageenglld:pubmed
pubmed-article:2835476pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:citationSubsetIMlld:pubmed
pubmed-article:2835476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2835476pubmed:statusMEDLINElld:pubmed
pubmed-article:2835476pubmed:monthMaylld:pubmed
pubmed-article:2835476pubmed:issn0022-3565lld:pubmed
pubmed-article:2835476pubmed:authorpubmed-author:BylundD BDBlld:pubmed
pubmed-article:2835476pubmed:authorpubmed-author:MurphyT JTJlld:pubmed
pubmed-article:2835476pubmed:authorpubmed-author:Ray-PrengerCClld:pubmed
pubmed-article:2835476pubmed:issnTypePrintlld:pubmed
pubmed-article:2835476pubmed:volume245lld:pubmed
pubmed-article:2835476pubmed:ownerNLMlld:pubmed
pubmed-article:2835476pubmed:authorsCompleteYlld:pubmed
pubmed-article:2835476pubmed:pagination600-7lld:pubmed
pubmed-article:2835476pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:meshHeadingpubmed-meshheading:2835476-...lld:pubmed
pubmed-article:2835476pubmed:year1988lld:pubmed
pubmed-article:2835476pubmed:articleTitleAlpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype.lld:pubmed
pubmed-article:2835476pubmed:affiliationDepartment of Pharmacology, School of Medicine, University of Missouri, Columbia.lld:pubmed
pubmed-article:2835476pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2835476pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2835476lld:pubmed